Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 Ubiquitin-Protein Ligase Parkin is a key enzyme involved in the ubiquitin-proteasome system and mitochondrial quality control. As an E3 ubiquitin ligase, it facilitates the attachment of ubiquitin to target proteins, marking them for degradation or other cellular processes like mitophagy. Mutations in the PRKN gene, which encodes parkin, are a major cause of early-onset Parkinson's disease, highlighting its critical role in neuronal survival and function.
Not applicable, target is an enzyme and there are no commonly known drugs that directly target it. Research efforts are underway to develop parkin activators or modulators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 Ubiquitin-Protein Ligase Parkin (Parkin).